The pseudokinase mixed lineage kinase domain-like protein (MLKL) is a key component of tumor necrosis factor (TNF)-induced necroptosis and plays a crucial role in necroptosis execution. However, the mechanisms that control MLKL activity are not completely understood. Here, we identify the molecular chaperone Hsp90 as a novel MLKL-interacting protein. We show that Hsp90 associates with MLKL and is required for MLKL stability. Moreover, we find that Hsp90 also regulates the stability of the upstream RIP3 kinase. Interference with Hsp90 function with the 17AAG inhibitor destabilizes MLKL and RIP3, resulting in their degradation by the proteasome pathway. Furthermore, we find that Hsp90 is required for TNF-stimulated necrosome assembly. Disruption of Hsp90 function prevents necrosome formation and strongly reduces MLKL phosphorylation and inhibits TNFinduced necroptosis. Consistent with a positive role of Hsp90 in necroptosis, coexpression of Hsp90 increases MLKL oligomerization and plasma membrane translocation and enhances MLKL-mediated necroptosis. Our findings demonstrate that an efficient necrotic response requires a functional Hsp90. Cell Death and Disease (2016) 7, e2089; doi:10.1038/cddis.2015.390; published online 11 February 2016
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The receptor-interacting serine-threonine kinase RIP1 and its family member RIP3 have crucial roles in tumor necrosis factor (TNF)-induced necroptosis. [2] [3] [4] [5] [6] Upon TNF stimulation, RIP1 binds to RIP3 via the RIP homotypic interaction motif. [4] [5] [6] RIP3 then recruits the pseudokinase mixed lineage kinase domainlike protein (MLKL) to form a multiprotein complex referred to as the 'necrosome' to trigger necroptosis. 7, 8 MLKL binds to RIP3 through its pseudokinase domain. The phosphorylation of RIP3 at Ser227 is required for MLKL binding. 7 Within the necrosome, RIP3 phosphorylates MLKL at Thr357 and Ser358. 7 These phosphorylation events induce a conformational change in MLKL, which leads to MLKL activation. 9 Upon activation, MLKL forms oligomers and translocates to the plasma membrane to execute necrotic cell death through a mechanism not well understood. [10] [11] [12] [13] [14] [15] MLKL consists of two domains, the N-terminal helical domain (amino acids , and the C-terminal pseudokinase domain (amino acids 179-471). 7, 9 The N-terminal region is the death effector domain. The pseudokinase domain is a regulatory domain, which is responsible for binding to the upstream RIP3 kinase. The indispensable role of MLKL in necroptosis has been demonstrated in MLKL − / − mice. 9, 16 Despite MLKL has an important role in necroptosis, little is known about its regulation. Here, we report the identification of the molecular chaperone heat shock protein 90 (Hsp90) as a novel MLKL-interacting protein using yeast two-hybrid screen. We show that Hsp90 is required for MLKL and RIP3 stability. Disruption of Hsp90 function prevents necrosome assembly and inhibits TNF-induced necroptosis. Our results suggest that Hsp90 has an important role in TNF-triggered necroptosis.
Results

Identification of Hsp90 as an MLKL-interacting protein.
To better understand the regulation of MLKL, we sought to identify MLKL-interacting proteins using a yeast two-hybrid screen. We screened a human bone marrow cDNA library with MLKL (1-178aa.) as bait. The screen identified a clone encoding Hsp90, as confirmed by sequencing, to be a novel MLKL-interacting protein ( Figure 1a) . To confirm the MLKL-Hsp90 interaction in mammalian cells, 293T cells were transfected with Flag-tagged Hsp90α and Myc-tagged MLKL. Extracts from the transfected cells were subjected to immunoprecipitation with an anti-Myc antibody, and the immunoprecipitates were probed with anti-Flag antibody for the presence of Flag-Hsp90α. As shown in Figure 1b We also observed that endogenous Hsp90 associates with endogenous MLKL in Hela cells (Figure 1d ). These results demonstrate that Hsp90 physically interacts with MLKL in cells.
To determine the MLKL region involved in the interaction with Hsp90, Myc-tagged full-length MLKL and two MLKL deletion mutants were coexpressed with Flag-Hsp90α in 293T cells. A coimmunoprecipitation assay was performed with anti-Myc antibody. As shown in Figure 1e , both Myc-MLKL (1-178) and Myc-MLKL (179-471) co-precipitated with Flag-Hsp90α. The binding of Myc-MLKL (1-178) to FlagHsp90α in 293T cells is consistent with our yeast two-hybrid screen result. Previous studies showed that the association of protein kinases with the Hsp90/cdc37 complex usually occurs through the catalytic kinase domain. 17 Our results suggest that the pseudokinase MLKL interacts with Hsp90 through its C-terminal pseudokinase domain as well as N-terminal helical region. (Figures 3c and d) . The proteasome inhibitor MG132 prevented the loss of MLKL protein and caused it to accumulate in a Triton X-100-insoluble cellular fraction (Figure 3e) . A similar effect has been reported for Raf and PDK-1 previously. 20, 21 This result suggests that a proteasome-mediated pathway degrades MLKL in the absence of Hsp90. Taken together, these results demonstrate the binding of Hsp90 to MLKL is critical for MLKL stabilization.
A previous study described that RIP1 is also an Hsp90-associated kinase. Disruption of Hsp90 function by the Hsp90 inhibitor geldanamycin (GA) resulted in the degradation of RIP1 and blockage of TNF-induced NF-κB activation. 22 We examined if Hsp90 also regulates the stability of the downstream RIP3 kinase. Figures 3f and g show that the expression levels of both overexpressed and endogenous RIP3 were greatly reduced in 17AAG-treated cells, suggesting that Hsp90 also controls RIP3 stability. Supporting this notion, we found that Hsp90 interacted with both ectopically expressed and endogenous RIP3 (Figures 1g and 4f) .
Next, we determined the half-life of MLKL after 17AAG treatment. As Figure 3h shown, the half-life of MLKL in control cells was 428 h. 17AAG preincubation markedly destabilized MLKL and reduced the half-life of MLKL to 12 h (Figure 3j ).
Hsp90 is essential for TNF-induced necroptosis. To assess the cellular role of Hsp90 in TNF-induced necroptosis, we tested the effect of the Hsp90-specific inhibitor 17AAG on TNF-induced necroptosis. The human colorectal cancer HT29 cells were left untreated or treated with the combination of TNF (T), Smac mimetic (S) and the pan-caspase inhibitor z-VAD-fmk (Z). HT29 cells underwent necroptosis in response to TSZ stimulation. As expected, TSZ-induced necroptosis was blocked by the RIP1 kinase inhibitor, necrostatin-1 (Nec-1). Of interest, 17AAG pretreatment inhibited TSZ-induced necroptosis in a concentrationdependent manner (Figures 4a and b, Supplementary  Figures S3 and S4) . Next, we examined the phosphorylation of MLKL by western blotting using a phospho-MLKL-specific antibody. As shown in Figure 4c , TSZ induced robust MLKL phosphorylation, which was blocked by Nec-1. Consistent with inhibition of necroptosis, 4125 nM 17AAG pretreatment strongly reduced phosphorylation of MLKL. 17AAG also severely inhibited oligomerization and plasma membrane translocation of MLKL following TSZ stimulation in HT29 cells (Figures 4d and e) . Of note, in this experiment while high concentration of 17AAG (250 nM) resulted in degradation of RIP1, RIP3 and MLKL, and strongly suppressed TNFinduced necroptosis; low concentration of 17AAG (125 nM) significantly inhibited phosphorylation of MLKL, RIP1 and possibly RIP3 without markedly affecting their protein levels. The phosphorylation of RIP1 was represented by the RIP1 bands shift in SDS-PAGE (Figure 4c ). These results, together with the results obtained in the MLKL regulation study in 293T cells (Figure 2 ), suggest that in addition to controlling the stability of RIP1, RIP3 and MLKL, Hsp90 also regulates their activity.
As the RIP1/RIP3/MLKL necrosome is a critical signaling platform for MLKL activation and TNF-induced necroptosis, we then examined if Hsp90 regulates necrosome assembly. We performed a coimmunoprecipitation assay with anti-RIP3 antibody. As shown in Figure 4f , TSZ stimulated the binding of RIP1 and MLKL to RIP3. 17AAG preincubation disrupted the Hsp90-RIP1-RIP3-MLKL complex and severely inhibited the formation of necrosome. Of interest, Hsp90 formed complex with RIP3 and probably with RIP1 and MLKL in HT29 cells 
Discussion
In this study, we have demonstrated that the molecular chaperone Hsp90 is a novel MLKL-interacting protein. We have shown that Hsp90 is essential for the stabilization of MLKL. In addition, we find that Hsp90 is required for RIP3 stability. We show that complex formation with Hsp90 is a prerequisite for the activation of RIP3 and MLKL and for the formation of necrosome in response to TNF stimulation. Disruption of Hsp90 function induces the degradation of MLKL and RIP3 and inhibits TNF-induced necroptosis. Our results demonstrate that Hsp90 regulates MLKL and RIP3 stability and is essential for TNF-induced necroptosis. These findings, together with two recent studies reporting that Hsp90 controls RIP3 function/stability 23, 24 and an earlier study describing RIP1 is an Hsp90 kinase client, 22 reveal that Hsp90 regulates the function of all the three components of the RIP1/RIP3/ MLKL cascade, which mediates TNF-triggered necroptosis. Intriguingly, previous reports suggested that pretreatment with the Hsp90 inhibitor GA protects Jurkat cells from DD receptor-induced necroptosis and disruption of Hsp90 function reverts TNFR1-induced necroptosis to apoptosis, although the underling mechanisms were not understood well at that time. 2, 25 A significant number of protein kinases form complexes with Hsp90 as a prerequisite for activation and/or assembly into functional complexes. Hsp90 contributes to the stabilization and maturation of these kinases and maintains them in their functionally active conformations. 17 The requirement of Hsp90 for the function of MLKL and RIP3 provides new evidences for the control of kinase activities by Hsp90. We demonstrated that Hsp90 is essential for the stabilization of MLKL and RIP3 proteins. It is conceivable that regulation of MLKL and RIP3 stability is an important step in the formation of necrosome in response to TNF stimulation. By directly modulating the stability of RIP1, RIP3 and MLKL, Hsp90 may hence control the signal-transducing capacity of these kinases. In addition to regulating their stability, Hsp90 may act as a molecular chaperone to assist the folding and maturation of RIP1, RIP3 and MLKL. Hsp90 has been shown to help to maintain the steroid receptor in a conformation competent for the binding of the hormone. 17 It is tempting to speculate that Hsp90 may assist MLKL to adopt multiple conformational states that facilitate or inhibit interactions with regulatory partners such as RIP3. Alternatively, Hsp90 could regulate the susceptibility to post-translational modification of MLKL by RIP3 and facilitate the conformational transition of MLKL from 'inactive state' to 'activated state'. Consistent with this idea, we found that overexpression of Hsp90 enhances the oligomerization of MLKL in 293T cells (Figure 2c) . Intriguingly, in line with our finding, overexpression of the Hsp90 co-chaperone Cdc37 increases the oligomerization and activation of IRAK-1 in 293T cells. 26 Hsp90 may also facilitate necrosome assembly. We observed that Hsp90 associates with the RIP1-RIP3-MLKL complex (Figure 4f ). It seems that the complex formation of Hsp90 with RIP1-RIP3-MLKL is required for necrosome assembly, as disrupting the Hsp90-RIP1-RIP3-MLKL complex with 17AAG strongly inhibits TNF-stimulated necrosome formation (Figure 4f ). Hsp90 may not recruit RIP3 and MLKL directly to RIP1; it may instead keep RIP3 and MLKL in a conformation able to respond to appropriate stimuli. Hsp90 could also have a role in the translocation of necrosome from the cytoplasm to the plasma membrane. It has been demonstrated that Hsp90/Cdc37 associates with the IKK complex and is required for trafficking of IKK from the cytoplasm to the membrane. Inhibition of Hsp90 prevented the recruitment of the IKK complex to TNFR1. 27 In addition, it was shown that Hsp90 is essential for the Ras-dependent trafficking of Raf kinase from the cytosol to the plasma membrane, and GA treatment blocked Raf translocation. 18, 28 Our results demonstrated that 17AAG preincubation inhibits TNF-induced translocation of MLKL to the plasma membrane (Figure 4e ), suggesting that Hsp90 has an important role in trafficking of the necrosome from the cytoplasm to the membrane.
Hsp90 has been shown to be released from its clients upon activation, for example, in the case of steroid receptor, Hsp90 dissociates from the receptor upon ligand binding; 29 and in the case of CDK4, Hsp90 is released from the active CDK4/cyclin D complex before it translocates into the nucleus to promote cell cycle progression. 30 We observed that a significant amount of Hsp90 is released from the RIP1-RIP3-MLKL complex following necrosome formation (Figure 4f ). This result suggests that although Hsp90 is required for TNF-induced necrosome assembly, it might not be a part of the final necrosome complex.
In conclusion, the results we have presented here and those reported by earlier studies [22] [23] [24] provide a molecular basis for the inhibitory effect of Hsp90 inhibitors on TNF-induced necroptosis. Previous studies suggested that IKK kinases are additional protein kinases involved in TNFR1 signaling that also depend on Hsp90 for their functions. 27, 31 Our findings together with those studies demonstrate that Hsp90 modulates the activity of multiple components of TNFR1 signaling pathways (for example, RIP1, RIP3, MLKL and IKK kinases) and reveal that Hsp90 has crucial roles in TNF-mediated activation of NF-κB and necroptosis. Necroptosis has been implicated in mediating multiple human inflammatory diseases. 1 Pharmacological inhibitors of Hsp90 could be potential therapeutic agents for treatment of human diseases characterized by necrosis and inflammation.
